Agency begins 'swift' enforcement actions

Share this article:

Less than three weeks after FDA commissioner Margaret Hamburg pledged better enforcement against firms violating agency laws and regulations, swifter and more aggressive actions by the agency are already being felt as the agency dismantles a controversial Bush administration directive that required all FDA Warning Letters to be screened by the Office of Chief Counsel (OCC).

FDA presenters at a University of Rhode Island College of Pharmacy “GMP by the Sea” conference appeared to be energized by the new enforcement posture. One industry questioner welcomed the end of OCC Warning Letter reviews, but he was also concerned that as a result “we may have a lack of consistency and uniformity in what Warning Letters are issued for by districts around the country.

FDA's Division of Field Investigations director Mike Rogers noted that all domestic Warning Letters will continue to have product center review and concurrence for consistency purposes.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Reimagining healthcare? We want to hear about it.
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters


More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric